Abstract:e16202 Background: Adjuvant therapy may have an important role in decreasing recurrence rates and improve survival in selected pts with HCC following surgical resection. However, there is no standard treatment options or strategies. This study aimed to investigate the safety and efficacy of donafenib combined with anti-PD-1 antibody as adjuvant therapy for HCC pts with high risks of recurrence. Methods: This prospective, open-label, single-arm study planned to enroll 30 pts who had undergone radical surgery and were diagnosed as HCC confirmed by histology or cytology with any of the following risk factors: a) Microvascular invasion (MVI); b) Satellite nodules in specimens; c) >3 tumor nodules; d) Portal vein tumor thrombosis (excluded main portal vein invasion). Donafenib combined with anti-PD-1 antibody was initiated at 4 to 8 weeks after surgical resection and continued for up to six months. The primary endpoint was the cumulative 1-year recurrence-free survival rate (RFSR). The secondary endpoints were recurrence-free survival (RFS), overall survival, and safety. Results: As of December 31st, 2022, a total of 23 pts received donafenib plus anti-PD-1 antibody (toripalimab) with a mean follow-up of 7.6 months (safety set). The most common risk factor was MVI (91%). 20 pts were included in efficacy set (three pts were excluded due to ineligibility), of whom 16 pts had one risk factor and four had two. Intrahepatic recurrence occurred in 3 pts (15%) and no extrahepatic metastasis or death was reported. The RFSR at one year was 83.0% (90%CI, 61.6%-93.1%) in all the pts from efficacy set, 81.9% (90%CI, 59.6%-92.6%) and 92.3% (90%CI, 66.0%-98.5%) in pts with MVI and MVI-low risk, and 85.1% (90%CI, 59.6%-95.1%) in pts with only one risk factor. The median RFS was not reached. The incidence of grade 3 adverse events related to donafenib and/or toripalimab was 52.2% (12/23). No pts had grade 4/5 adverse events. Adverse events leading to withdrawal of any and both treatments occurred in six (26.1%) and one (4.3%) pts, respectively. The most common grade 3 treatment-related adverse events (occurred in more than one patient) were palmar-plantar erythrodysesthesia syndrome (17.4%), rash (17.4%), alanine aminotransferase increased (13.0%), and aspartate aminotransferase increased (8.7%). Conclusions: These results were consistent with earlier reports. The combination of donafenib and toripalimab may be a promising adjuvant therapy for pts with MVI, satellite nodules or multiple tumor after hepatectomy. No safety issues were noted. Clinical trial information: NCT04418401 . [Table: see text]

Peretinoin as an adjuvant therapy for hepatocellular carcinoma

Peretinoin, an Acyclic Retinoid, for the Secondary Prevention of Hepatocellular Carcinoma

The acyclic retinoid Peretinoin inhibits hepatitis C virus replication and infectious virus release in vitro

Peretinoin, an Acyclic Retinoid, Inhibits Hepatitis B Virus Replication by Suppressing Sphingosine Metabolic Pathway In Vitro

Acyclic retinoid targets platelet-derived growth factor signaling in the prevention of hepatic fibrosis and hepatocellular carcinoma development

Peretinoin, an acyclic retinoid, suppresses steatohepatitis and tumorigenesis by activating autophagy in mice fed an atherogenic high-fat diet

Chemoprevention of hepatocellular carcinoma: concept, progress and perspectives

Retinoid roles in blocking hepatocellular carcinoma

Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects

Chemoprevention of hepatocellular carcinoma in chronic hepatitis C

The Safety and Efficacy of Donafenib Combined with Anti-Pd-1 Antibody As Adjuvant Therapy for Patients (pts) with Hepatocellular Carcinoma (HCC): Updated Results of a Phase 2 Study.

Acyclic retinoid in the chemoprevention of hepatocellular carcinoma (review)

A Systematic Review and Meta-Analysis of Randomized Controlled Trails : Adjuvant Interferon Therapy for Hepatocellular Carcinoma

Preventive Treatments for Recurrence after Curative Resection of Hepatocellular Carcinoma - A Literature Review of Randomized Control Trials

Supportive therapies for prevention of hepatocellular carcinoma recurrence and preservation of liver function

Recent treatments to Hepatocellular Carcinoma Cancer(HCC): update and outlook

Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma

Why Adjuvant and Neoadjuvant Therapy Failed in HCC. Can the New Immunotherapy Be Expected to Be Better?

Chemoprevention against hepatocellular carcinoma

Postoperative adjuvant immunotherapy for high-risk hepatocellular carcinoma patients

Inhibition of hepatocellular carcinoma by PegIFNα-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study